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Mizoribine (MZB) is an imidazole nucleoside and an immunosuppressive agent. The immunosuppressive eﬀect of MZB has been
reported to be due to the inhibition of DNA synthesis in the S phase of the cell cycle. Because of its relative lack of toxicity, during
thepastdecadeMZBhasbeenfrequentlyusedinsteadofazathioprineasacomponentofimmunosuppressivedrugregimens.MZB
is being used to treat renal transplantation patients, IgA nephropathy, lupus erythematosus, and childhood nephrotic syndrome
(NS), and some recent studies have assessed the eﬃcacy of oral MZB pulse therapy for severe lupus nephritis, steroid-resistant NS,
and frequently relapsing-steroid-dependent NS. This review summarizes the published ﬁndings on the eﬃcacy of MZB for renal
disease including IgA nephropathy, lupus nephritis, and NS, as well as of oral MZB pulse therapy for severe lupus nephritis and
NS, and also the mechanism of the eﬀect of oral MZB pulse therapy on the lymphocyte cell cycle.
Copyright © 2009 Yukihiko Kawasaki. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Eupenicillium brefeldianum, an ascomycetes harvested from
the soil of Hachijo Island, Tokyo, Japan, in 1971, produces
mizoribine (MZB). MZB is a nucleoside of the imidazole
class, and was found to have weak antimicrobial activity
against Candida albicans, but it proved ineﬀective against
experimental candidiasis [1].
MZB inhibits the de novo purine biosynthesis of purines,
but unlike azathioprine (AZT), it is not incorporated into
nucleic acids in the cell. Instead, after phosphorylation,
misoribine-5 -monophosphate (MZB-5 P) inhibits guano-
sinemonophosphate(GMP)synthesisbyantagonisticblock-
ing of inosine monophasphate dehydrogenase (IMPDH)
and GMP-synthetase in the pathway from inosine [5 -]
monophasphate (IMP) to GMP in the purine synthesis
system. MZB was found to inhibit both humoral and cellular
immunity by selectively inhibiting lymphocyte proliferation,
which led to its development as an immunosuppressive
agent.TheclinicaleﬃcacyofMZBasanimmunosuppressant
forrenaltransplantationwasinvestigatedinvariousJapanese
institutions during the period from 1978 to 1982, and
in 1984, MZB was approved by the Japanese Ministry
of Health, Labour and Welfare as a drug indicated for
the prevention of rejection in renal transplantation [2, 3].
Recently, it has been most commonly used in combination
with other immunosuppressants, such as cyclosporine (CyA)
or tacrolimus, and corticosteroids, for transplantation.
The characteristics of MZB, which diﬀerentiate it from
AZT, are the lack oncogenicity shown in animal experiments
and association with a low incidence of severe adverse drug
reactions, for example, myelosuppression and hepatotox-
icity, clinically [1–3]. Since these ﬁndings suggested that
MZB would be useful for long-term immunosuppressive
therapy, several clinical trials of MZB for the treatment
of autoimmune diseases were carried out, and its clinical
usefulness was obvious. In addition to its approval for the
prevention of rejection after renal transplantation, MZB
has been approved in Japan for the treatment of lupus
nephritis (1990), rheumatoid arthritis (1992), and primary
nephritic syndrome (1995), and in these diseases, it has often
been used in combination with corticosteroids and/or anti-
inﬂammatory drugs [4].
Nevertheless, because of its relatively low-eﬃcacy MZB
is still not widely used clinically. It is one of the causes that
blood concentration of MZB does not increase enough. The
peakbloodlevelsofMZBduringstandardMZBtherapy,that
is, 3mg/kg daily in three divided dose, has been reported to2 Clinical and Developmental Immunology
be approximately 0.5μg/mL [5], lower than the concentra-
tion required to inhibit experimental human MLRs, which
occurs in the 3.0–6.0μg/mL concentration range [6]. To
increase the its peak blood levels, MZB was has recently been
administrated in a single daily dose of 150mg or at a total
daily dose of 6–10mg/kg in a single dose or two divided
doses, twice a week, and has been reported to be eﬀective.
This review summarizes the mechanism of action of
MZB and the published ﬁndings on the eﬃcacy of MZB for
renaldiseaseincludingIgAnephropathy,lupusnephritis,and
NS, and on the eﬃcacy of oral MZB pulse therapy for severe
lupus nephritis and NS, and on the mechanism of the eﬀect
of oral MZB pulse therapy on the lymphocyte cell cycle.
2. Mechanismof Action of MZB
MZB has a very speciﬁc mechanism of action on the lym-
phocytes that inhibits their proliferation without interfering
with purine synthesis in other cell types. Purine synthesis
occurs via two separate pathways: a de novo pathway and
a salvage pathway. In the de novo pathway, the ribose
phosphate portion of purine nucleotides is derived from 5-
phosphoribosyl 1-pyrophosphate (PRPP), which is synthe-
sized from ATP and ribose 5-phosphate, and lymphocytes
are primarily dependent on the de novo pathway [7–9].
In the salvage pathway, purine bases, sugars, and other
products are essentially recycled, and most cells, including
polymorphonuclear leukocytes and neurons, are able to
utilize the salvage pathway. The speciﬁcity of the inhibitory
eﬀect of MZB on lymphocytes proliferation is attributable
to the fact that it acts on the de novo pathway, of purine
biosynthesis alone and does not act on the salvage pathway
in purine biosynthesis.
Sakaguchi et al. [10, 11] investigated the mechanism of
action of MZB in mouse lymphoma cell line L5178Y, which
isverysensitivetoMZB,andfoundthatMZBstronglyinhib-
ited both DNA synthesis and RNA synthesis, but not protein
synthesis. AZT, which also exerts its immunosuppressive
eﬀect through antimetabolism, is known to be incorporated
into nucleic acid instead of thioguanosine 5 -triphosphate
[12]. MZB, however, was found not to be incorporated into
DNAorRNAinastudyusing[14C]MZB,butdidspeciﬁcally
inhibit nucleic acid synthesis [13]. MZB almost completely
suppresses the growth of L5178Y cells at a concentration of
10−5 M. The addition of 2 × 10
−4 M GMP to this culture
system liberates the cells from growth inhibition by MZB,
but other purine nucleotides or pyrimidine nucleotides do
not reverse the eﬀect of MZB [13]. Based on these ﬁndings,
MZB can be concluded to inhibits the synthesis of GMP
from IMP in the purine metabolism pathway, without being
incorporated into DNA or RNA.
Koyama and Tsuji [14]demonstratedthatMZBismetab-
olized into an active form, MZB 5 -P, by adenosine kinase
(AK) in carcinoma cells. They used cells that were resistant
to various drugs and had been obtained by treating mouse
mammarycarcinomacells(FM3A)withN-methyl-N
 -nitro-
N-nitrosoguanidine. The MZB-resistant (MZBr)m u t a n t s
thatwereobtainedasaresultwere15–19-foldlesssensitiveto
MZB than wild-type cells. The MZBr mutants were capable
of incorporating radioactivity from ring-labeled adenosine
into their acid-insoluble macromolecular fraction the same
as wild-type cells, but hypoxanthine-guanine phosphor-
ribosyl-transferase deﬁcient (HGPRT
T-) mutants derived
from the MZBr cells did not incorporate the radioactivity
at all or incorporated it at a much lower rate. Exogenous
adenosine enters the purine nucleotide pool via two diﬀerent
pathway. In one pathway, it is phosphorylated by AK and
then metabolized to adenosine 5 -monophosphate (AMP),
whereas in the other, pathway it is converted to inosine
through the action of adenosine deaminase, and the inosine
is then converted to hypoxanthine (by purine nucleoside
phosphorylase) and is metabolized into IMP (by HGPRT).
The two pathways of adenosine metabolism described above
are blocked. Enzyme assays of cell-free extracts of the MZBr
mutants revealed that their AK activity was less than 3%
of the AK activity found in wild-type cells. Based on these
ﬁndings, it was clear that MZB suppressed cell growth in
the presence of AK, strongly suggesting that MZB exerts its
suppressiveeﬀectoncellgrowthonlyafterbeingmetabolized
to MZB-5 Pb yA K .
Kusumi et al. [15] investigated the inhibitory eﬀects of
MZB and MZB-5 P using cell-free extracts from rat liver
on IMPDH and Walker sarcoma cells on GMP synthetase.
MZB inhibited neither enzyme, whereas MZB-5 P inhibited
both, and its Ki values were 10−8 MI M P D Ha n d1 0 −5 M
for GMP synthetase. These results demonstrated that the
suppressive eﬀect of MZB on cell growth is attributable
to MZB-5 P and not to MZB itself, and that MZB-5 P
primarily inhibits IMPDH, and secondarily inhibits GMP
synthetase, thereby inhibiting two enzymes that act in two
sequential steps in the GMP synthesis process. MZB-5 P
appears to almost completely inhibits guanine nucleotide
synthesis. Quantitative changes in purine nucleotides in
MZB-treated cells have also been investigated to conﬁrm
the enzyme-inhibiting eﬀect of MZN-5 P. However, L5178Y
cells, in which de novo purine nucleotide synthesis had been
arrested with aminopterin, were incubated with 14C-labeled
hypoxanthine, in the presence or absence of MZB. When
the purine nucleotides were isolated, and the radioactivity in
each of the nucleotides was measured, the amount of GMP-
containing guanine nucleotide was found to have decreased
considerably after incubation in the presence of MZB, in
comparison to incubation in the absence of MZB.
Turka et al. [16, 17] investigated the eﬀect of MZB
on human peripheral blood cells stimulated with anti-CD3
monoclonal antibodies or pharmacological mitogens and
found that MZB inhibited T cell proliferation by 10–100%
in a dose-dependent manner in relation to all stimuli tested.
MZB also caused a dose dependent decrease in GTP pools,
andadditionofguanosinebothpreventedtheGTPdepletion
and reversed its antiproliferative eﬀect at all but the highest
doses of MZB.
2.1. In Vitro Eﬀects
2.1.1. Growth Inhibitory Eﬀects of MZB on Various Cells.
Mizuno et al. investigated the growth inhibitory eﬀect of
MZB on several cell lines and showed that MZB had a strongClinical and Developmental Immunology 3
inhibitory eﬀect on lymphoma cell line L5178Y and L-cells,
with IC50 values >100 [1].
2.1.2. Eﬀect of MZB on Lymphocytes Stimulated with Mitogens
or Allogenic Cells. Kamata et al. [2] studied the eﬀect
of MZB on lymphocytes from beagle dogs and observed
dose-dependent inhibition of the blastogenic response of
lymphocytes to concanavalin A, phytohemagglutinin, and
pokeweed mitogen, as well as of the mixed lymphocyte
reaction (MLR).
Ichikawa et al. [3] investigated the eﬀect of MZB on
proliferation by human lymphocytes and showed that MZB
suppressesd their blastogenic response to all three of the
above mitogens, and the MLR. The mitogen responses and
MLR were signiﬁcantly suppressed at a concentration of
10μg MZB/mL, and the 50% inhibition doses of MZB
against the three mitogens and on the MLR were between
1.0 and 10μg/mL.
2.1.3. Novel Mechanism of Action of MZB. Itoh et al. [18]
used MZB aﬃnity column chromatography and porcine
kidney cytosols to identify proteins that speciﬁcally bind
MZB using MZB aﬃnity column chromatography and
porcine kidney cytosols. By increasing MZB in the eluant
fromthecolumn,twomajorproteins(withmolecularmasses
of 60 and 43kDa) were detected by sodium dodecyl sulfate-
(SDS-) polyacrylamide gel electrophoresis. Based on the
amino acid sequence analysis of these proteins, 60- and
43-kDa MZB-binding proteins were identiﬁed with heat
shock protein (HSP) 60 and cytosolic actin, respectively.
A considerable amount of actin was also eluted from the
aﬃnity column by nucleotides, but a very low quantity of
HSP60 was eluted under the same conditions. On the other
hand, HSP60 was eluted as a major protein in the eluant that
was eluted preferentially, with nucleotide followed by MZB.
Actin was also detected in the eluant, but the quantity of the
protein was very low. These results indicated that HSP60 had
ah i g ha ﬃnity to MZB, and the interaction was also observed
on surface plasmon resonance analysis.
The 14-3-3 proteins form a highly conserved family
of acidic, dimeric proteins that are widely distributed
among eukaryotic cells. The 14-3-3 proteins interact with
many proteins involved in cellular signaling, including the
glucocorticoid receptor (GR), and the 14-3-3/GR interac-
tion enhances the transcriptional activity of the receptor.
Takahashi et al. showed that MZB aﬀected the conformation
of 14-3-3 proteins and enhanced the interaction between
GR and 14-3-3 dose-dependently in vitro. MZB also has a
stimulatory eﬀect on transcriptional activation by the GR.
These ﬁndings point to the possibility that regulation of
the GR function via 14-3-3 proteins may be one of the
mechanisms of the therapeutic eﬀect of MZB [19].
2.1.4. Absorption, Distribution, Metabolism, and Excretion
of MZB. The absorption, distribution, metabolism, and
excretionofMZBwereinvestigatedafterorallyadministering
14C-MZB to rats [20], MZB was rapidly absorbed, and
its blood concentrations peaked at 1.5 hours, then rapidly
declined. MZB was almost completely eliminated within 24
hours. Whole-body autoradiography revealed high levels of
radioactivity in the stomach, small intestine, liver, kidney,
spleen, and thymus one hour after administration. Within
24 hours, 85% of the administered dose was excreted in the
urine and 1.0% in the bile. Inverse isotope dilution analysis
showed that unchanged 14C-MZB accounted for more than
99% of the radioactivity in the plasma one hour after dosing,
and the 85% of MZB excreted in the urine within 24 hours
after administration was unchanged.
When a 100mg oral dose of MZB was administrated
to six kidney-transplantrecipients with good renal function,
and a serum creatinine levels under 2.7mg/dL, their serum
MZB concentration peaked at about 2.3g/mL two hours
after the dose, then gradually decreased T1/2 value was 2.2
hours. About 82% of the oral dose of MZB had been
excreted in the urine of the transplant patients six hours
after administration [21]. The serum MZB concentration
of patients with renal dysfunction remained high even 24
hours after administration. The rate of MZB elimination
from serum is closely correlated with renal function [22].
2.1.5. Blood MZB Levels and Oral MZB Pulse Therapy. The
peak blood level of MZB, during regular MZB therapy, that
is, 3mg/kg daily in three divided, the peak levels of the
d r u gh a sb e e nr e p o r t e dt ob ea p p r o x i m a t e l y0 . 5μg/mL [5].
It has recently been reported that peak blood MZB levels in
the 3.0–6.0μg/dL are suﬃcient to inhibit the human MLR
[6]. Thus, the higher serum MZB concentrations achieved
by pulse therapy are needed to inhibit disease activity.
Stypinski et al. [23] reported that higher doses than the
current clinical dosage of 2–5mg/kg day may be needed to
maintain the eﬃcacy of MZB. The safety, tolerability and
pharmacokinetics of MZB in two clinical trials of higher-
dose MZB administration to healthy male volunteers have
been reported. Forty-eight healthy White male nonsmokers
participated in two randomized, double-blind, placebo-
controlled trials: 32 in a single-dose study (3, 6, 9, and
12mg/kg)and16inamultiple-dosestudy(6mg/kg/dayonce
daily for 5 days or twice daily for 7 days), and standard
assessmentsofsafety,tolerability,andpharmacokineticswere
performed. The safety proﬁles in both studies were generally
unremarkable,exceptforelevatedserumuricacidconcentra-
tions at the highest dose (12mg/kg/day) in the multiple-dose
study. After oral MZB reached its peak serum concentrations
within 2-3 hours and was eliminated mostly via the kidney
(65–100% of dose), its serum half-life was 3 hours. Only
the 12 mg/kg/day group had trough concentrations that
were within the therapeutic window (trough concentrations
>0.5 but <3μg/mL). Based on the safety proﬁle of MZB
and current pharmacokinetic information, a new starting
dose in the 6–12mg/kg/day range is recommended for
kidney transplant patients in the up to 3-month acute phase
following transplantation. Kawasaki et al. reported a peak
serum MZB concentration of 1.4–4.8μg/mL and a morning
trough serum MZB concentration of 0–0.3 in 8 patients with
N Sw h e nM Z Bw a sg i v e no r a l l yi nad o s eo f1 0m g / k gb o d y
weight daily (maximum total daily dose 500mg) in three
divided doses, 2 days a week (Figure 1)[ 24, 25]. In addition,
Kawasaki et al. found that the peak serum concentration was
3.0–5.1μg/mL, the AUC 0–4 of MZB was 7.0–16.0μg·h/mL4 Clinical and Developmental Immunology
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Figure 1: Change in the serum MZB concentration of each patient
on the days when MZB was administered.
and the morning trough serum MZB concentration was
0μg/mL (Table 1), when MZB was given orally in a dose of
6mg/kg body weight daily (maximum total dose 300mg)
twice a week in 11 patients with frequently relapsing
NS [26].
3.ClinicalEfﬁcacy
3.1.RenalTransplantation. TheclinicaleﬃcacyofMZBasan
immunosuppressant for renal transplantation was assessed
in various Japanese institutions during the period between
1978 and 1982, the period when immunosuppression was
mainly achieved with AZT and corticosteroids and before
the immunophilin-binding drugs cyclosporine (CyA) or
tacrolimus were available. During that period, 200 to 300
renal transplants were performed in Japan each year. In one
study the immunosuppressive eﬀect of triple-drug therapy
(MZB+AZT+corticosteroid) in 57 cases was compared
with the immunosuppressive eﬀect obtained in 72 historical
controls treated with AZT+corticosteroid alone. The graft
survival rate in the group that received MZB, was 89.6%, and
signiﬁcantly higher (P<. 05) than the (74.6%) in the group
that did not receive MZB [4].
From 1989 through 1998, Tanabe et al. [27]e x e c u t e d
a prospective, randomized study to evaluate the immuno-
suppressive eﬀect of MZB in 116 renal transplantation
patients. Patients received MZB or AZT for 9 years after
transplantation. The 9-year patient survival rate of the MZB
group and AZT group was 88% and 83%, respectively.
The 9-year graft survival rates of the MZB group was 58%
and 52%, respectively, and diﬀerences between the groups
i ng r a f ts u r v i v a lr a t ea n dp a t i e n ts u r v i v a lr a t ew e r en o t
signiﬁcant. However, AZT had to be switched to MZB in 16
patients (27.6%) because of adverse eﬀects, which consisted
of myelosuppression in 11 patients and liver dysfunction in
5 patients. No MZB-related adverse eﬀects occurred, and
discontinuation of MZB was never necessary. According to
these results, MZB has almost the same immunosuppressive
eﬀe c ta sA Z Tb u tm a n yf e w e ra d v e r s ee ﬀects.
3.2. IgA Nephropathy (IgAN). Primary immunoglobulin A
(IgA) nephropathy (IgAN) is a disease that was ﬁrst reported
in 1968 by Berger and Hinglais and is characterized by
microhematuriaandproteinuriaclinically,andbydeposition
of IgA histologically. IgAN is the most common form
of chronic glomerulonephritis worldwide, and in up to
30% of patients it progresses to end-stage renal failure.
Since severe IgAN could not be controlled with a single
drug, combinations of drugs with diﬀerent mechanism
of action, including corticosteroids, immunosuppressive
agents, antiplatelet drugs, and anticoagulation, have been
used. The rationale for using prednisolone and MZB in
IgAN is that corticosteroids and immunosuppressive agents
reduce IgA production and minimize the abnormal immune
response and inﬂammatory events following glomerular IgA
deposition. Warfarinanddilazepdihydrochloride areusedto
inhibit the mediators of glomerular damage.
Kaneko et al. [28] showed that MZB was eﬀective
against moderately severe childhood IgAN because of its
antiproteinuric eﬀect and lower toxicity. Nagaoka et al. [29]
further found that MZB could be used as an alternative drug
to treat moderately severe childhood IgAN because MZB
resulted in a signiﬁcant reduction of proteinuria and hema-
turia with histological improvement and caused far fewer
complications than the conventional immunosuppressants.
To evaluate the eﬃcacy of prednisolone, warfarin, dilazep
dihydrochloride combined with MZB (multiple drug com-
bination therapy (PWDM)) for diﬀuse IgAN in childhood,
Kawasaki et al. retrospectively compared the clinical features
and pathology ﬁndings of diﬀuse IgAN patients treated with
PWDM with those of patients who received multiple-drug
therapy without MZB (PWD) and multiple-drug therapy in
combination with methylprednisolone pulse therapy (PWD-
pulse) (Tables 2, 3,a n d4). The duration of follow-up (years)
was 8.9 ± 5.2 in the PWD group, 8.1 ± 3.9 in the PWD-
pulse group, and 7.7 ± 3.8 in the PWDM group. At the
most recent follow-up examination, mean urinary protein
excretion (mg/m2/h) was 17±10 in the PWD group, 22±20
in the PWD-pulse group, and 6±6 in the PWDM group,
and had decreased signiﬁcantly in the PWDM group in
comparison with the other groups. The activity index (AI)
in all three groups was lower at the second biopsy than that
at the ﬁrst biopsy (5.1 ± 0.8v e r s u s6 .5 ± 2.1i nP W Dg r o u p ,
P<. 05; 5.6 ± 0.9v e r s u s6 .6 ± 1.7 in PWD-pulse group,
P<. 01; and 4.5 ± 1.0v e r s u s6 .8 ± 1.9 in the PWDM group,
P<. 01). The chronicity index (CI) in the PWD group and
PWD-pulse group at the second biopsy was higher than at
the ﬁrst biopsy (7.3±1.4v e r s u s4 .8±1.0 in the PWD group,
P<. 01; 8.1 ± 2.0v e r s u s5 .3 ± 0.9 in the PWD-pulse group,
P<. 01), but was unchanged in the PWDM group. At the
mostrecentfollow-upexamination,twopatient(10%)inthe
PWDgroup,3(15%)inthePWD-pulsegroup,and12(60%)
in the PWDM group had renal insuﬃcieny, 1 patient (4.8%)
in the PWD group, 3 (15%) in the PWD-pulse group, and
none (0%) in the PWDM group had normal urine, 7 patient
(35%) in the PWD group, 6 (30%) in the PWD-pulse group,
and 7 (35%) in the PWDM group had minimal urinary
abnormalities; while 11 patient (52%) in the PWD group, 8
(40%) in the PWD-pulse group, and 1 (5%) in the PWDMClinical and Developmental Immunology 5
Table 1: Changes in serum MZB concentration and AVC0-4 in the 11 patients who received oral MZB pulse therapy.
Case Serum MZB concentration (μg/mL) AUC0-4 (μg·h/mL)
C0 C1 C2 C3 C4 C24
1 0.0 2.8 4.5 2.9 2.1 0.0 12.3
2 0.0 1.4 2.2 4.2 3.4 0.0 11.2
3 0.0 1.8 3.5 4.4 3.9 0.0 13.6
4 0.0 1.7 2.5 3.8 1.9 0.0 9.9
5 0.0 4.1 5.1 3.9 2.9 0.0 16.0
6 0.0 1.2 3.0 4.2 4.9 0.0 13.3
7 0.0 2.2 3.8 3.6 2.5 0.0 12.1
8 0.0 2.2 2.7 3.0 2.5 0.0 10.4
9 0.0 1.4 2.7 3.3 2.4 0.0 9.8
10 0.0 1.4 2.5 2.6 2.0 0.0 8.5
11 0.0 1.6 1.8 2.2 1.4 0.0 7.0
Serum MZB was measured immediately before the morning dose of MZB (C0) and 1 hour (Cl), 2 hours (C2), 3 hours (C3), 4 hours (C4), and 24 hours (C24)
after the dose.
AUC =area under the concentration-time curve; MZB=mizoribine.
group had persistent nephropathy; ﬁnally, 1 patient (5%) in
the PWD group, 3 (15%) in the PWD-pulse group, and none
(0%) in the PWDM group had renal insuﬃciency. These
results suggest that PWDM is more eﬀective than PWD
or PWD-pulse in reducing the proteinuria and histological
severity in patients with IgAN. In addition, we prospectively
investigated the eﬃcacy of PWDM against IgAN. After 6
months of treatment mean urinary protein excretion had
decreased signiﬁcantly compared to before the start of
treatment [30]. The incidence of hematuria after PWDM
therapywaslowerthanthatbeforethestartoftreatment.The
AI decreased signiﬁcantly from 4.8±2.1 at the ﬁrst biopsy to
2.3±1.7atthesecondbiopsy(P<. 001)andtheCIdecreased
signiﬁcantly from 4.1 ± 1.9 at the ﬁrst biopsy to 2.7 ± 2.4
at the second biopsy (P<. 05). Macrophage inﬁltration and
alpha-smooth muscle actin positive cells in the glomerulus
and interstitial region decreased signiﬁcantly between before
therapy and after therapy, and the serum IgA levels (mg/dL)
was lower after therapy (197.4 ± 78.1 versus 266.5 ± 105.0,
P<. 01, resp.). At the most recent follow-up examination,
noneofthe34patientshadrenalinsuﬃciency.Theseﬁndings
suggested that the prednisolone plus MZB combination
therapy is eﬀective in patients who are at risk of progression
of IgAN. The rationale for using prednisolone and MZB in
IgAN is that corticosteroids and immunosuppressive agents
reduce IgA production and minimize the abnormal immune
response and inﬂammatory events following glomerular IgA
deposition. Warfarinanddilazepdihydrochlorideareusedto
inhibit the mediators of glomerular damage. Most of the side
eﬀects were mild and well controlled, and all were reversible.
Severe side eﬀects attributable to the prednisolone plus MZB
combination therapy regimen were relatively rare and the
regimen was well tolerated and safe in all patients.
Yoshikawaetal.[31]treated23childrenwithsevereIgAN
with MZB, prednisolone, heparin-warfarin, and dipyri-
damole, and evaluated their eﬃcacy and safety. The primary
endpoint, a urine protein/creatinine ratio <0.2, was achieved
in 18 patients during the two-year treatment period. The
cumulative proteinuria resolution rate determined by the
Kaplan-Meiermethodwas80.4%,andmedianproteinexcre-
tion decreased from 1.19g/m2/day to 0.05g/m2/day (P<
.0001). The median percentage of glomeruli showing scle-
rosis was unchanged in comparison with before treatment.
No patients required a change treatment. In conclusion, the
eﬃcacy and safety of the MZB combination seem acceptable
for treating children with severe IgAN.
3.3. Nephrotic Syndrome. During the period between 1989
and 1991, Koshikawa et al. [32] performed a 24-week,
prospective, randomized, double-blind, placebo-controlled,
comparative trial to assess the eﬃcacy of MZB in patients
with steroid-resistant NS, and the eﬃcacy was assessed in a
total of 158 patients (80 in the MZB group and 78 in the
placebo group). The global improvement rate, evaluated by
the physicians in charge, was signiﬁcantly higher in the MZB
group (33.8%) than in the placebo (14.1%) group (P<. 05),
and the diﬀerence between the improvement rates in the
two groups became more marked when the subgroup taking
corticosteroids at daily doses below 20mg as a prednisolone
rquivalent at baseline (30.0% versus 5.3%, P<. 05) was
evaluated. Laboratory studies revealed an average 25.2%
reduction in the urinary protein level in the MZB group
as opposed to 10.0% in the placebo group (P<. 0). The
incidences of side eﬀects in the MZB group (13.6%) and
placebo groups (11.9%) did not diﬀer signiﬁcantly.
Yoshioka et al. [33] showed that MZB signiﬁcantly
decreased the relapse rate and prolonged remission in a
subgroup of NS patients <10 years old, and that it can be
useful in young children, who generally have a higher relapse
rate than older children.
Kawasaki et al. [25] evaluated the eﬃcacy of oral MZB
pulse therapy (10mg/kg body weight daily (maximum total
daily dose 500mg) in three divided doses, 2 days a week)
in one child with cyclosporine-dependent steroid-resistant
NS and eight children with frequently relapsing steroid-
dependent NS, and found that four patients had no sub-6 Clinical and Developmental Immunology
Table 2: Comparison between patient characteristics and laboratory ﬁndings in the three groups at the time of the ﬁrst renal biopsy.
PWD (n = 21) PWD-pulse (n = 20) PWDM (n = 20)
Age at ﬁrst renal biopsy,
years 11.5 ±2.91 3 .1 ±4.31 2 .9 ±3.2 n.s.
Time between onset of
symptoms and biopsy,
months
6.2 ±6.96 .0 ±4.95 .5 ±5.1 n.s.
Male:female ratio 11 : 10 12 : 8 11 : 9 n.s.
Urinary protein excretion,
mg/m2/hr 69 ±55 72 ±49 78 ±68 n.s.
Patients with severe
proteinuria
(<50mg/m2/hr)
110 ±79 (n = 12) 99 ±36 (n = 13) 101 ±57 (n = 12) n.s.
Patients with mild
proteinuria
(<50mg/m2/hr)
36 ±11 (n = 9) 42 ±8( n = 7) 38 ±12 (n = 8) n.s.
Hematuria (macroscopic) 21 (13) 20 (14) 20 (12) n.s.
Serum albumin, g/L 31 ±43 2 ±63 0 ±5 n.s.
Serum creatinine, μmol/L 60 ±22 64 ±28 61 ±25 n.s.
24-hour Ccr,
mg/min/1.73m2 84 ±33 82 ±35 79 ±29 n.s.
n.s.: not signiﬁcant.
sequent relapses (responders). Prednisolone and CyA were
discontinued in two of the four responders, and CyA was
discontinuedintheothertwo.Althougheachoftheﬁveother
patients (non-responders) experienced a single subsequent
relapse, after MZB pulse therapy the dosages of prednisolone
and CyA were signiﬁcantly reduced in comparison with
before MZB pulse therapy. The peak blood concentration of
MZBintheresponderswashigherthaninthenonresponders
(3.6 ±0.9v e r s u s1 .8 ±0.4μg/mL, P<. 05).
Kawasaki et al. [26] on the other hand, demonstrated
the eﬃcacy of single dose oral MZB pulse therapy (6mg/kg
body weight daily (maximum total daily dose 300mg) twice
a week) in 11 patients with frequently relapsing steroid-
dependent NS and found that eight of the 11 had no
subsequent relapses (responders), and prednisolone could
be discontinued [25]. Although 2 of the other 3 patients
(nonresponders) had one relapse and the remaining patient
had two relapses, the dosage of prednisolone and frequency
of relapse after oral MZB pulse therapy were signiﬁcantly
lower than before oral MZB pulse therapy. The peak blood
concentration and AUC 0–4 of MZB in the responders were
higher than in the nonresponders. None of patients had
severe adverse eﬀects, such as uricacidemia, leucopenia, liver
dysfunction, or alopecia.
In addition, Ohtomo et al. [34] showed that high-
dose MZB therapy appeared to be eﬀective in reducing
cyclosporine exposure as well as in decreasing the fre-
quency of relapses in patients with frequently relapsing
steroid-dependent NS who are also cyclosporine-dependent.
Thus, these ﬁndings suggested that oral MZB pulse ther-
apy may be eﬀective in some patients with cyclosporine-
dependent steroid-resistant NS and frequently relapsing
steroid-dependent NS.
3.4. Lupus Nephritis. Yumura et al. [35] investigated whether
maintenance therapy with MZB and prednisolone could
improveimmunity,reduceproteinuria,preventrenalrelapse,
a n da l l o wr e d u c t i o no ft h es t e r o i dd o s ei ns e v e r ep r o l i f e ra t i v e
lupus nephritis patients. Long-term maintenance therapy
with MZB and prednisolone was evaluated in ten patients
with biopsy-proven severe proliferative lupus nephritis, and
0.5g or more proteinuria even after treatment by plasma
exchange and/or with pulse methylprednisolone. MZB at an
average dose of 140 ± 10 (100–200)mg was administered
2–3 times daily/day in combination with prednisolone. The
averagedurationofMZBmaintenancetherapywas89.7±5.5
(70–126) months. All patients were females, and their mean
age was 43.0±3.3 years. A signiﬁcant decrease in proteinuria
was noted two years after the start of combination therapy
(P = .0016). The serum creatinine levels of all patients
remained unchanged throughout the treatment and follow-
up period, even during renal relapses. The C3 and CH50
levels became normal as the proteinuria decreased. None
of the patients developed serious side eﬀects during MZB
treatment. A signiﬁcant steroid-sparing eﬀect was observed
three years after the start of MZB therapy (P = .0025).
Based on the results of long-term follow-up, maintenance
therapy with low-dose prednisolone combined with MZB
can eliminate proteinuria and has a steroid-sparing eﬀect.
Early initiation of therapy can protect patients with severe
proliferative lupus nephritis against renal relapses without
s e r i o u ss i d ee ﬀects.
Tanaka et al. [36] assessed oral MZB pulse therapy for
lupus nephritis and reported that oral MZB pulse therapy
was eﬀective in ﬁve patients with a long history of systemic
lupus erythematosus (SLE), including four patients with
proliferativelupusnephritis (WHOclassIV)andone patientClinical and Developmental Immunology 7
Table 3: Comparison between laboratory ﬁndings in the three groups at the latest follow-up examination.
PWD (n = 21) PWD-pulse (n = 20) PWDM (n = 20)
The duration from
initiation of therapy (years)
8.9 ±5.28 .1 ±3.97 .7 ±3.8
Urinary protein excretion
(mg/m2/hr)
17 ±10(a) 22 ±20(b) 6 ±6(a,b)
Patients with severe
proteinuria
(<50mg/m2/hr)
19 ±9(c) 25 ±22(d) 5 ±5(c,d)
Patients with mild
proteinuria
(<50mg/m2/hr)
14 ±8(e) 18 ±15(f) 7 ±6(e,f)
Hematuria (macro) (cases) 15 (5)
(g) 14 (6)
(h) 5( 0 )
(g,h)
Serum albumin (g/L) 34 ±43 2 ±63 6 ±5
Serum creatinine (μmoI/L) 52 ±39(e,i) 78 ±59(e,i) 44 ±15(i)
(a,c,d,e,f,g,h)P<. 05.
(b,i)P<. 01.
Table 4: Comparison between clinical stages in the three groups at the time of the ﬁrst renal biopsy and the most recent follow-up
examination.
First renal biopsy Most recent follow-up examination
PWD (n = 21) PWD-pulse (n = 20) PWDM (n = 20) PWD (n = 21) PWD-pulse (n = 20) PWDM (n = 20)
Stage 0 0/21 (0%) 0/20 (0%) 0/20 (0%) 2/21 (10%)
(e) 3/20 (15%)
(f) 12/20 (60%)
(e,f)
Stage 1 0/21 (0%) 0/20 (0%) 0/20 (0%) 7/21 (35%) 6/20 (30%) 7/20 (35%)
Stage 2 17/21 (81%)
(a) 14/20 (70%)
(a,b) 15/20 (75%)
(b) 11/21 (52%)
(g) 8/20 (40%)
(h) 1/20 (5%)
(g,h)
Stage 3 4/21 (19%)
(c) 6/20 (30%)
(c,d) 5/20 (25%)
(d) 1/21 (5%)
(i) 3/20 (15%)
(i,j) 0/20 (0%)
(j)
(e,f,g,h)P<. 05.
(a,b,c,d,i,j)n.s.: not signiﬁcant.
with WHO class II lupus nephritis, in whom remission had
been achieved by treatment with high-dose corticosteroids
combined with cytotoxic agents. The patients were treated
with MZB 5–10mg/kg daily (up to 500mg daily) in a single
daily dose two days a week (Monday and Thursday) for
over 24 months. The dose of the concomitant corticosteroid
was gradually reduced or continued unchanged. On pre-
sentation, the urinary protein excretion, serum complement
hemolytic activity (CH50) and serum anti-dsDNA antibody
titer were 1.7 ± 1.0g/day , 16.6 ± 3.8U/mL (normal, 23–
46U/mL) and 143.7 ± 151.1IU/mL (normal, <12.0IU/mL),
respectively. At the most recent follow-up examination, after
a mean interval of 31 months (24–34 months) since the start
of MZB pulse therapy, the urinary protein excretion and
serum anti-dsDNA antibody titer had signiﬁcantly decreased
(0.3 ± 0.2g/day and 18.5 ± 19.1IU/mL, resp.; P<. 05),
and the serum CH50 value had returned to within normal
range (33.6 ± 7.8U/mL, P<. 05). Despite the reduced
minimum dose of prednisolone required to maintain clinical
remission at the time of the post-treatment evaluation after
MZB pulse therapy as compared with that at the time of the
pretreatment evaluation (9.0 ± 4.5v e r s u s1 7 .5 ± 7.9mg/day;
P = .0656), the calculated ﬂare rate signiﬁcantly decreased
(0.15 ± 0.2v e r s u s0 .6 ± 0.11 times per year; P<. 05). The
serum creatinine level remained within the normal range
in all the participants in the study, and the platelet count
of two patients with chronic thrombocytopenia increased
following the MZB pulse therapy. No serious adverse eﬀects
were observed. These ﬁndings suggest that long-term MZB
pulse therapy may be the treatment of choice for selected
lupus nephritis patients who are at high risk of relapse.
Futhermore, Tanaka et al. [37] reported on the eﬃcacy of
the oral MZB pulse protocol for induction therapy for newly
diagnosed childhood-onset systemic lupus erythematosus
(SLE). Five consecutive newly diagnosed SLE patients with
biopsy-proven lupus nephritis were recruited for an open-
label trial of prednisolone and MZB intermittent pulse
therapy (10mg/kg 2 days a week for 12 months). Data on
the renal response and serologic lupus activity were collected
prospectively. The baseline characteristics of the patients
were: mean age, 11 years; urinary protein/creatinine ratio
(U-prot./cre.), 0.99 ± 0.91; serum complement hemolytic
activity (CH50), 10.6 ± 1.3 (normal, 23–46U/mL); serum
anti-dsDNA antibody titer, 258.6 ± 125.5IU/mL (normal,
<12.0IU/mL); serum creatinine, 0.5 ± 0.1mg/dL; and
European Consensus Lupus Activity Measurement index
(ECLAM), 7.4 ± 1.1. The primary endpoint was the interval
until the development of a ﬂareup of SLE. Despite gradual
tapering of the prednisolone dose, signiﬁcant improvement
in all parameters examined was observed at 3, 6, and
12 months of treatment in comparison with the baseline
values. After 12 months of therapy, a complete response
was achieved in all of the patients, except 1 patient with
poor drug compliance. Marked histological improvement8 Clinical and Developmental Immunology
Table 5: Adverse reactions to MZB.
Renal Transplantation Lupus Nephritis Rheumatoid Arthritis Nephrotic Syndrome Total
Number of surveyed cases 916 275 3478 240 4909
Number of adverse reaction cases 186 33 462 38 719
Number of adverse reaction episodes 229 47 658 49 983
Incidence of adverse reaction cases 20.31% 12.00% 13.28% 15.83% 14.65%
Incidence of Adverse Reactions (%)
Blood
Leukopenia 6.99 2.55 0.20 0.83 1.63
Thrombocytopenia 0.98 0.73 0.14 0.33
Anaemia 0.44 0.36 0.72 0.42 0.63
Infection
Pneumonia 0.55 0.03 0.42 0.14
Mycosis pulmonary 0.55 0.10
Herpes zoster 0.76 1.45 0.17 0.35
Other viral infection 0.76 0.03 0.16
Liver
Hepatic function abnormal 4.15 1.09 1.18 2.29 1.81
Hypersensitivity
Rash 1.09 1.64 2.08 1.32
Prurigo 1.09 0.77
Metabolic
Uric acid increased 1.64 1.45 0.43 2.50 0.81
Gastrointestinal
Celialgia 0.36 2.21 1.67 1.67
Anorexia 0.98 1.09 1.12 0.83 1.08
Vomiting 0.55 1.09 1.18 0.42 1.02
Nausea 0.11 1.09 0.23 0.24
Diarrhea 0.22 0.73 0.63 0.42 0.55
Stomatitis 0.76 0.73 0.66 0.42 0.67
Skin
Epilation 1.09 1.09 0.29 1.67 0.55
Note. Listed adverse reactions occurred in 0.5% of cases of greater for at least one indication of MZR.
was conﬁrmed at the second renal biopsy in two patients
found to have severe lupus nephritis at the ﬁrst renal biopsy.
No serious adverse eﬀects were observed. Thus, the MZB
pulse protocol combined with prednisolone for induction
therapy may be the treatment of choice for selected young
SLE patients.
In addition, Nozu et al. [38] treated ﬁve adolescents with
SLE MZB 300mg/day orally in two divided doses, which
is twice the conventional dose for adults. Patients 1 and 2
had been treated with prednisolone and CyA, but as the
duration of CyA administration became long, it was replaced
with 300mg MZB, and the transition was accomplished
smoothly. Patient 3 experienced repeated recurrences during
treatment with PSL and CyA or CPM, but the symptoms
were controlled by the addition of MZB. In patients 4 and 5,
symptom control with prednisolone alone was judged to be
diﬃcult, and concomitant treatment with MZB 300mg was
started and enabled a decrease in the dose of prednisolone.
The Cmax (C2) of MZB was 1.33μg/mL or higher in all ﬁve
patients, and the eﬃcacy of the treatment was satisfactory.
Hyperuricemia developed as a side eﬀect in two patients, but
it resolved in one of them after reducing the dose of MZB
and it resolved spontaneously in the other patient while the
treatment was continued. Temporary exacerbation of hair
loss was observed in two patients, but it resolved in both
of them after a few months. It was possible to administer
MZB could be administered at a high dose eﬀectively and
safely. However, monitoring of the serum uric acid level was
necessary.High-doseMZBtherapyshowedsuﬃcienteﬃcacy
and safety to warrant its application to the treatment of
steroid-dependent pediatric patients with SLE.
3.5. Other Renal Disease. There had been a few reports
on the eﬃcacy of MZB against other renal disease besides
IgAN, nephrotic syndrome, and lupus nephritis. Imaizumi
et al. [39] reported that steroid pulse and MZB combined
with plasmapheresis may be an eﬀective treatment in a
patient with focal segmental glomerulosclerosis complicated
by CyA-induced leukoencephalopathy. Hirayama et al. [40]
investigated the eﬃcacy of MZB in patients at high risk of
relapse of ANCA-associated renal vasculitis. Their study wasClinical and Developmental Immunology 9
conducted on 5 patients, 4 with myeloperoxidase (MPO)
anti-neutrophil cytoplasmic antibody- (ANCA-) associated
renal vasculitis and 1 with proteinase 3 (PR3) ANCA-
associated renal vasculitis, in whom remission had been
achieved by treatment with methylprednisolone pulse ther-
apy, corticosteroids, and cyclophosphamide. MZB therapy
was started when their ANCA titers were found to be above
the normal range after the remission. The median time
between the initial treatment and ﬁrst dose of MZB was 40.0
months (range: 24–51 months), and the median follow-up
period was 13.0 months (range: 6–16 months). Before the
start of MZB therapy, none of the patients had experienced
a relapse, and their ANCA titers 3 months before the start
of MZB therapy were below the limit of detection. When
MZB administration was started, the ANCA titers of all of
the patients were elevated (median MPO-ANCA, 101 ELISA
units (EU); range: 65–154 EU; PR3-ANCA, 55 EU), but no
newsymptomsorsignsofrelapsewerenoted.After2months
ofMZBtherapy,only1patienthadexperiencedarelapse,but
the ANCA titers of all of the other patients had decreased,
and in 3 patients they had become normal. Considering the
balance between suppression of disease activity and adverse
eﬀects of treatment, MZB may be useful as preemptive
treatment for patients with ANCA-associated renal vasculitis
at high risk of relapse.
3.6. Adverse Reactions. Various kinds of clinical trials and
a postmarketing surveillance study involved a total of 4906
cases receiving MZB therapy for kidney transplantation
and three disease patients. The principal adverse reactions
associated with the use of MZB were leucopenia, abnormal
hepatic function, rash, increased levels of uric acid, and
vomiting. Adverse reactions that occurred at a rate of 0.5%
or greater in the patient population for at least one induction
of MZB are presented in Table 5 [4].
4. Conclusions
Thereviewhassummarizedthepublishedﬁndingsregarding
the eﬃcacy of MZB in the treatment of renal disease
including IgAN, lupus nephritis and NS, of oral MZB pulse
therapy for severe lupus nephritis, and NS, and of the
mechanism of the eﬀect oral MZB pulse therapy on the
lymphocyte cell cycle. It will, of course, be necessary to
further evaluate the eﬃcacy of MZB and oral MZB pulse
therapy for the above renal diseases by means of randomized
control trials with long-term follow-up before MZB is used
worldwide.
References
[1] K. Mizuno, M. Tsujino, M. Takada, M. Hayashi, and K.
Atsumi, “Studies on bredinin. I. Isolation, characterization
and biological properties,” Journal of Antibiotics, vol. 27, no.
10, pp. 775–782, 1974.
[2] K.Kamata,M.Okubo,E.Ishigamori,etal.,“Immunosuppres-
sive eﬀect of bredinin on cell-mediated and humoral immune
reactions in experimental animals,” Transplantation, vol. 35,
no. 2, pp. 144–149, 1983.
[3] Y. Ichikawa, H. Ihara, and S. Takahara, “The immunosuppres-
sive mode of action of mizoribine,” Transplantation, vol. 38,
no. 3, pp. 262–267, 1984.
[4] H. Ishikawa, “Mizoribine and mycophenolate mofetil,” Cur-
rent Medicinal Chemistry, vol. 6, no. 7, pp. 575–597, 1999.
[5] T. Hamasaki, M. Mori, Y. Kinoshita, T. Saeki, and T. Sakano,
“Mizoribine in steroid-dependent nephrotic syndrome of
childhood,” Pediatric Nephrology, vol. 11, no. 5, pp. 625–627,
1997.
[6] K. Sonda, K. Takahashi, K. Tanabe, et al., “Clinical phar-
macokinetic study of mizoribine in renal transplantation
patients,” Transplantation Proceedings,vol. 28, no. 6, pp. 3643–
3648, 1996.
[ 7 ]A .C .A l l i s o n ,T .H o v i ,R .W .E .W a t t s ,a n dA .D .B .W e b s t e r ,
“Immunological observations on patients with Lesch Nyhan
syndrome, and on the role of de novo purine synthesis in
lymphocyte transformation,” The Lancet, vol. 2, no. 7946, pp.
1179–1183, 1975.
[ 8 ]A .C .A l l i s o n ,T .H o v i ,R .W .W a t t s ,a n dA .D .W e b s t e r ,“ T h e
role of de novo purine synthesis in lymphocyte transforma-
tion,” Ciba Foundation Symposium, no. 48, pp. 207–224, 1977.
[9] T. Hovi, A. C. Allison, K. Raivio, and A. Vaheri, “Purine
metabolismandcontrolofcellproliferation,” CibaFoundation
Symposium, no. 48, pp. 225–248, 1977.
[10] K. Sakaguchi, M. Tsujino, M. Yoshizawa, K. Mizuno, and K.
Hayano, “Action of bredinin on mammalian cells,” Cancer
Research, vol. 35, no. 7, pp. 1643–1648, 1975.
[11] K. Sakaguchi, M. Tsujino, K. Mizuno, K. Hayano, and N.
Ishida, “Eﬀect of bredinin and its aglycone on L5178Y cells,”
Journal of Antibiotics, vol. 28, no. 10, pp. 798–803, 1975.
[12] G. A. LePage and J. P. Whitecar Jr., “Pharmacology of 6-
thioguanine in man,” Cancer Research, vol. 31, no. 11, pp.
1627–1631, 1971.
[13] K. Sakaguchi, M. Tsujino, M. Hayashi, K. Kawai, K. Mizuno,
andK.Hayano,“Modeofactionofbredininwithguanylicacid
on L5178Y mouse leukemia cells,” Journal of Antibiotics, vol.
29, no. 12, pp. 1320–1327, 1976.
[14] H. Koyama and M. Tsuji, “Genetic and biochemical studies
on the activation and cytotoxic mechanism of bredinin, a
potent inhibitor of purine biosynthesis in mammalian cells,”
Biochemical Pharmacology, vol. 32, no. 23, pp. 3547–3553,
1983.
[ 1 5 ]T .K u s u m i ,M .T s u d a ,T .K a t s u n u m a ,a n dM .Y a m a m u r a ,
“Dual inhibitory eﬀect of bredinin,” Cell Biochemistry and
Function, vol. 7, no. 3, pp. 201–204, 1989.
[16] L. A. Turka, J. Dayton, G. Sinclair, C. B. Thompson, and B.
S. Mitchell, “Guanine ribonucleotide depletion inhibits T cell
activation. Mechanism of action of the immunosuppressive
drug mizoribine,” Journal of Clinical Investigation, vol. 87, no.
3, pp. 940–948, 1991.
[ 1 7 ]J .S .D a y t o n ,L .A .T u r k a ,C .B .T h o m p s o n ,a n dB .S .
Mitchell, “Comparison of the eﬀects of mizoribine with those
of azathioprine, 6-mercaptopurine, and mycophenolic acid
on T lymphocyte proliferation and purine ribonucleotide
metabolism,” Molecular Pharmacology, vol. 41, no. 4, pp. 671–
676, 1992.
[18] H.Itoh,A.Komatsuda,H.Wakui,A.B.Miura,andY.Tashima,
“Mammalian HSP60 is a major target for an immunosuppres-
sant mizoribine,” Journal of Biological Chemistry, vol. 274, no.
49, pp. 35147–35151, 1999.
[19] S. Takahashi, H. Wakui, J.-A. Gustafsson, J. Zilliacus, and
H. Itoh, “Functional interaction of the immunosuppressant
mizoribine with the 14-3-3 protein,” Biochemical and Biophys-
ical ResearchCommunications, vol. 274, no. 1, pp. 87–92, 2000.10 Clinical and Developmental Immunology
[20] J. Murase, K. Mizuno, K. Kawai, et al., “Absorption, dis-
tribution, metabolism and excretion of bredinin in rats,”
Pharmacometrics, vol. 15, no. 5, pp. 829–835, 1978 (Japanese).
[21] R. Kusaba, O. Otubo, T. Inou, M. Tsujino, and H. Ishikawa,
“Studiesonpharmacokineticsofbredinin,” Japanese Journal of
Transplantation, vol. 17, supplement, p. 585, 1982 (Japanese).
[22] K. Takada, S. Muranishi, S. Asada, et al., “Clinical phar-
macokinetic study of bredinin in renal transplant patients,”
Transplantation, vol. 17, supplement, p. 595, 1982 (Japanese).
[23] D. Stypinski, M. Obaidi, M. Combs, M. Weber, A. J. Stewart,
and H. Ishikawa, “Safety, tolerability and pharmacokinetics
of higher-dose mizoribine in healthy male volunteers,” British
Journal of Clinical Pharmacology, vol. 63, no. 4, pp. 459–468,
2007.
[24] Y. Kawasaki, J. Suzuki, A. Takahashi, M. Isome, R. Nozawa,
and H. Suzuki, “Mizoribine oral pulse therapy for steroid-
dependentnephroticsyndrome,”PediatricNephrology,vol.20,
no. 1, pp. 96–98, 2005.
[25] Y. Kawasaki, M. Hosoya, S. Kobayashi, et al., “Oral mizoribine
pulsetherapyforpatientswithsteroid-resistantandfrequently
relapsing steroid-dependent nephrotic syndrome,” Nephrology
Dialysis Transplantation, vol. 20, no. 10, pp. 2243–2247, 2005.
[26] Y. Kawasaki, K. Takano, M. Isome, et al., “Eﬃcacy of single
dose of oral mizoribine pulse therapy two times per week
for frequently relapsing nephrotic syndrome,” Journal of
Nephrology, vol. 20, no. 1, pp. 52–56, 2007.
[27] K. Tanabe, T. Tokumoto, N. Ishikawa, et al., “Long-term
results in mizoribine-treated renal transplant recipients: a
prospective, randomized trial of mizoribine and azathioprine
under cyclosporine-based immunosuppression,” Transplanta-
tion Proceedings, vol. 31, no. 7, pp. 2877–2879, 1999.
[28] K. Kaneko, R. Nagaoka, Y. Ohtomo, and Y. Yamashiro,
“Mizoribine for childhood IgA nephropathy,” Nephron, vol.
83, no. 4, pp. 376–377, 1999.
[29] R. Nagaoka, K. Kaneko, Y. Ohtomo, and Y. Yamashiro,
“Mizoribine treatment for childhood IgA nephropathy,” Pedi-
atrics International, vol. 44, no. 2, pp. 217–223, 2002.
[30] Y. Kawasaki, J. Suzuki, N. Sakai, et al., “Eﬃcacy of pred-
nisoloneandmizoribinetherapyfordiﬀuseIgAnephropathy,”
American Journal of Nephrology, vol. 24, no. 1, pp. 147–153,
2004.
[31] N. Yoshikawa, K. Nakanishi, K. Ishikura, H. Hataya, K. Iijima,
and M. Honda, “Combination therapy with mizoribine for
severe childhood IgA nephropathy: a pilot study,” Pediatric
Nephrology, vol. 23, no. 5, pp. 757–763, 2008.
[32] S. Koshikawa, M. Sato, M. Narita, N. Sakai, and M. Naka-
jima, “Clinical evalution of an immunosuppressive drug,
mizoribine (HE-69) on steroid-resistant nephritic syndrome-
A multicenter double-blind comparison study with placebo,”
Kidney and Dialysis, vol. 34, p. 631, 1993 (Japanese).
[33] K. Yoshioka, Y. Ohashi, T. Sakai, et al., “A multicenter trial of
mizoribinecomparedwithplaceboinchildrenwithfrequently
relapsing nephrotic syndrome,” Kidney International, vol. 58,
no. 1, pp. 317–324, 2000.
[34] Y. Ohtomo, S.-I. Fujinaga, M. Takada, et al., “High-dose
mizoribine therapy for childhood-onset frequently relaps-
ing steroid-dependent nephrotic syndrome with cyclosporin
nephrotoxicity,” Pediatric Nephrology, vol. 20, no. 12, pp.
1744–1749, 2005.
[35] W. Yumura, S. Suganuma, K. Uchida, et al., “Eﬀects of long-
term treatment with mizoribine in patients with proliferative
lupus nephritis,” Clinical Nephrology, vol. 64, no. 1, pp. 28–34,
2005.
[36] H. Tanaka, K. Tsugawa, K. Suzuki, T. Nakahata, and E. Ito,
“Long-term mizoribine intermittent pulse therapy for young
patients with ﬂare of lupus nephritis,” Pediatric Nephrology,
vol. 21, no. 7, pp. 962–966, 2006.
[37] H. Tanaka, K. Tsugawa, E. Oki, K. Suzuki, and E. Ito,
“Mizoribine intermittent pulse protocol for induction therapy
for systemic lupus erythematosus in children: an open-label
pilot study with ﬁve newly diagnosed patients,” Clinical
Rheumatology, vol. 27, no. 1, pp. 85–89, 2008.
[38] K. Nozu, K. Iijima, I. Kamioka, et al., “High-dose mizoribine
treatmentforadolescentswithsystemiclupuserythematosus,”
Pediatrics International, vol. 48, no. 2, pp. 152–157, 2006.
[39] T. Imaizumi, Y. Kawasaki, H. Matsuura, et al., “Eﬃcacy of
steroidpulse,plasmapheresis,andmizoribineinapatientwith
focal segmental glomerulosclerosis,” Pediatric Nephrology, vol.
22, no. 8, pp. 1215–1218, 2007.
[40] K. Hirayama, M. Kobayashi, Y. Hashimoto, et al., “Treatment
with the purine synthesis inhibitor mizoribine for ANCA-
associated renal vasculitis,” American Journal of Kidney Dis-
eases, vol. 44, no. 1, pp. 57–63, 2004.